Dorota Hryniewiecka-Firlej, president of Pfizer Poland, discusses the current state of the Polish innovation landscape and importance of a tight-knit relationship between the innovative pharmaceutical market and the government for better patient outcomes. Furthermore, she highlights the strong R&D footprint of Pfizer Poland and their role in facilitating a domestic scientific breakthrough, as the most significant market for Pfizer in the region.
You are not only the president of Pfizer Poland, but also the president of the Employers Association of the Innovative Pharmaceutical Companies (INFARMA). What have been your key achievements over the last two years?
"We are working to ensure market access to our newest breast cancer treatments, that are not accessible to Polish patients."
